Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?

Transfusion

Volumn 58, Issue 9, 2018, Pages 2095-2101

  Jacquot, Cyril ^a,b   Delaney, Meghan ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; METHYLENE BLUE; POOLED PLASMA (HUMAN); FUROCOUMARIN DERIVATIVE;

BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; CRYOPRECIPITATION; ERYTHROCYTE; EXTRACORPOREAL PHOTOPHERESIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNITY; NOTE; PATHOGEN INACTIVATED BLOOD PRODUCT; PATIENT SAFETY; PEDIATRIC PATIENT; PEDIATRICIAN; PHOTOPHERESIS; PUVA; ADOLESCENT; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; BLOODBORNE BACTERIUM; CHILD; DRUG EFFECT; INFANT; MICROBIOLOGY; NEWBORN; PEDIATRICS; PRESCHOOL CHILD; RADIATION RESPONSE; STANDARDS; TREATMENT CONTRAINDICATION; ULTRAVIOLET RADIATION; VIROLOGY;

ADOLESCENT; BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CHILD; CHILD, PRESCHOOL; CONTRAINDICATIONS, PROCEDURE; FUROCOUMARINS; HUMANS; INFANT; INFANT, NEWBORN; METHYLENE BLUE; PATIENT SAFETY; PEDIATRICS; PHOTOPHERESIS; TRANSFUSION REACTION; ULTRAVIOLET RAYS;

EID: 85053197550     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14811     Document Type: Note

References (44)

1. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008;22:1-34.
2. Heddle NM, Boeckh M, Grossman B, et al. for the AABB Clinical Transfusion Medicine Committee. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion 2016;56:1581-7.
3. Leibson T, Koren G. Informed consent in pediatric research. Paediatr Drugs 2015;17:5-11.
4. AABB, ARC, ABC, ASBP. Circular of information for the use of human blood and blood components [Internet]. Bethesda: AABB; 2017 [cited 2018 Apr 12]. Available from: www.aabb.org/tm/coi/Documents/coi1017.pdf.
5. Van Aelst B, Devloo R, Zachee P, et al. Psoralen and ultraviolet A light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing. J Biol Chem 2016;291:24364-76.
6. Castiglia S, Mareschi K, Labanca L, et al. Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy 2014;16:750-63.
7. Gunnarskog JG, Kallen AJ, Lindelof BG, et al. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 1993;129:320-3.
8. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141:108-12.
9. Bruynzeel I, Bergman W, Hartevelt HM, et al. ‘High single-dose' European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991;124:49-55.
10. Di Biaso I, Di Maio L, Bugarin C, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 2009;87:1422-5.
11. Sniecinski I, Seghatchian J. Factual reflections and recommendations on extracorporeal photopheresis in pediatrics. Transfus Apher Sci 2017;56:118-22.
12. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database Syst Rev 2015;12:CD009898.
13. Ciaravino V, Hanover J, Lin L, et al. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009;49:985-94.
14. Ciaravi V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001;20:533-50.
15. Octapharma. Octaplas product insert [Internet]. Hoboken (NJ): Octapharma; [cited 2018 Apr 12]. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/ucm336161.pdf.
16. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. Pediatrics 1996;97:717-21.
17. Sills MR, Zinkham WH. Methylene blue-induced Heinz body hemolytic anemia. Arch Pediatr Adolesc Med 1994;148:306-10.
18. New H, Tinegate H, Hunt L, et al. Methylene blue-treated plasma. London: Joint UKBTS/HPA Professional Advisory Committee/SHOT; 2012.
19. Musso D, Richard V, Broult J, et al. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2014;54:2924-30.
20. Irsch J, Seghatchian J. Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: current position on methodological, clinical and regulatory aspects. Transfus Apher Sci 2015;52:240-4.
21. AABB. Listing of countries in which pathogen reduction technology systems and products are in use [Internet]. Bethesda: AABB; 2015 [cited 2018 Apr 12]. Available from: http://www.aabb.org/tm/eid/Documents/prt-systems-in-use-country-listing.pdf.
22. Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014;28:235-41.
23. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 2003;43:1481-92.
24. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept Blood System-treated plasma. Blood 2014;123:796-7.
25. Schmidt M, Hourfar MK, Sireis W, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion 2015;55:2104-12.
26. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011;38:19-31.
27. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52.
28. Rico S, Carter K, Benjamin RJ, et al. Piper study rationale and design: characterizing the incidence of acute respiratory distress syndrome in hematology-oncology patients following the transfusion of conventional or pathogen-reduced platelet components. Biol Blood Marrow Transplant 2016;22:S173-S4.
29. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
30. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004;87:82-90.
31. Rentas F, Harman R, Gomez C, et al. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007;47:240-7.
32. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
33. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-9.
34. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
35. Trakhtman P, Karpova O, Balashov D, et al. Efficacy and safety of pathogen-reduced platelet concentrates in children with cancer: a retrospective cohort study. Transfusion 2016;56(Suppl 1):S24-8.
36. Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
37. Salunkhe V, van der Meer PF, de Korte D, et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015;52:19-34.
38. Seghatchian J, Struff WG, Reichenberg S. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011;38:55-64.
39. Albert M, Lessin MS, Gilchrist BF. Methylene blue: dangerous dye for neonates. J Pediatr Surg 2003;38:1244-5.
40. Álvarez M, Luis-Hidalgo M, Bracho MA, et al. Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light. Transfusion 2016;56:831-6.
41. Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system--an update. Transfus Apher Sci 2012;46:221-9.
42. Ribeiro da Silva VC, da Motta Silveira FM, Barbosa Monteiro MG, et al. Photodynamic therapy for treatment of oral mucositis: Pilot study with pediatric patients undergoing chemotherapy. Photodiagnosis Photodyn Ther 2018;21:115-30. doi: 10.1016/j.pdpdt.2017.11.010. Epub 2017 Nov 22. PubMed PMID: 29175466.
43. Canadian Agency for Drugs and Technologies in Health (CADTH). Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. CADTH Technol Overv 2010;1:e0106.
44. Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003;85:88-95.